On October 19, 2020 Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, reported three poster presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 35th Anniversary Annual Meeting (SITC 2020) (Press release, Cue Biopharma, OCT 19, 2020, View Source [SID1234608294]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Title: Immuno-STATs: Leveraging protein engineering to expand and track antigen-specific T cells in vivo
Poster #: 623
Presenter: Steven Almo, Ph.D., co-founder
Date: Wednesday, November 11, 2020 from 5:15–5:45 p.m. EST and Friday, November 13, 2020 from 4:40–5:10 p.m. EST
Title: CUE-100 series Immuno-STATs from concept to the clinic: Leveraging protein engineering to stimulate and selectively deliver affinity-attenuated IL-2 to antigen-specific T cells
Poster #: 553
Presenter: Saso Cemerski, Ph.D., vice president and head, discovery and translational immunology
Date: Wednesday, November 11, 2020 from 5:15–5:45 p.m. EST and Friday, November 13, 2020 from 4:40–5:10 p.m. EST
Title: A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer
Poster #: 354
Presenter: Sara I. Pai, M.D., Ph.D., associate professor, Massachusetts General Hospital and Harvard Medical School, Boston
Date: Thursday, November 12, 2020 from 4:50–5:20 p.m. EST and Saturday, November 14, 2020 from 1–1:30 p.m. EST
"Data presented from these posters further demonstrate the therapeutic potential of our Immuno-STAT platform," said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. "We look forward to presenting preclinical data highlighting the IL-2 based CUE-100 series Immuno-STATs, as well as results from our ongoing open-label, dose escalation Phase 1 monotherapy trial with CUE-101 in patients with HPV16+ head and neck cancer."
About the CUE-100 Series
The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules. This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient. The binding affinity of IL-2 for its receptor has been deliberately attenuated to achieve preferential selective activation of tumor-specific effector T cells while reducing potential for effects on regulatory T cells (Tregs) or broad systemic activation, potentially mitigating the dose-limiting toxicities associated with current IL-2-based therapies.
About Immuno-STAT
Immuno-STAT biologics are designed for targeted modulation of disease-associated T cells in the areas of immuno-oncology and autoimmune disease. Each of our biologic drugs is designed using our proprietary scaffold comprising: 1) a peptide-MHC complex (pMHC) to provide selectivity through interaction with the T cell receptor (TCR), and 2) a unique co-stimulatory signaling molecule to modulate the activity of the target T cells.
The simultaneous engagement of co-regulatory molecules and pMHC binding mimics the signals delivered by antigen presenting cells (APCs) to T cells during a natural immune response. This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in highly targeted T cell modulation. Because our drugs are delivered directly in the patient’s body (in vivo), they are fundamentally different from other T cell therapeutic approaches that require the patients’ T cells to be extracted, modified outside the body (ex vivo), and reinfused.